New England Journal of Medicine Publishes Promising Phase 1/2 Data for Daraxonrasib in RAS-Mutant Lung Cancer

The New England Journal of Medicine (NEJM) has published Phase 1/2 clinical data for Revolution Medicines' daraxonrasib (RMC-6236), an oral RAS(ON) multiselective inhibitor, in patients with previously treated advanced RAS-mutant non-small-cell lung cancer (NSCLC). The study demonstrated objective responses across various dose groups, with higher response rates in specific ranges, supporting the drug's continued development into Phase 3 trials for a cancer type with limited targeted treatment options.